Biotech company OMass Therapeutics has moved into newly fitted R&D and office space at ARC Oxford.

Previous sites at Oxford and Nottingham will collaborate at the new 16,000 sq ft space. The expanding firm now has 55 employees.

ARC has refurbished the laboratory space to meet OMass’ scientific and technical requirements, including new facilities for chemistry and structural biology to support drug discovery. Office space has also been designed to enable collaborative working both on-site and virtually.

David Williams, director of leasing at ARC said: “We’re delighted to be supporting OMass Therapeutics on its growth journey. It’s a leading UK biopharma company at the forefront of innovation in drug discovery.

“The new building keeps it at the heart of a vibrant ecosystem of innovative companies in Oxford and offers access to communal, social and co-working spaces and a curated programme of events for campus members.”

The company’s development has also been supported by the appointment  of Winfried Barchet as vice president of immunology.

Ros Deegan, chief executive of OMass, said: “It is an exciting period of growth for OMass Therapeutics as we move to our new premises, bringing all our staff under one roof, and welcome Winfried to the senior leadership team.

“Winfried brings a wealth of expertise in immunology as we continue to execute on our plans to discover drugs for previously undrug-able targets, and ultimately, bring life changing medicines to patients.”

© Thames Tap (powered by

Sign up to receive our weekly free journal, The Forum here.